^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer

Excerpt:
The immunochemistry results showed that high XIAP expression levels inversely correlated with carboplatin response (P=0.03) and progression-free survival (P=0.0068) in patients with ovarian cancer….XIAP may be a novel target for the treatment of carboplatin-resistant ovarian cancer.
DOI:
10.2147/OTT.S171053